Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab... by Naohiro Watanabe, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Naohiro Wada, Ayako Shimizu, Tomoya Komori, Hirofumi Koike, Yukiko Sahashi, Atsushi Nakajima, Masato Yoneda

Get full text